
|Videos|April 26, 2022
Updates from Bausch and Lomb: US launch of FDA approved treatment for uveitis, new IOL toric calculator
Author(s)Kassi Filkins
Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
2
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
3
Expanding the ICRS toolkit: Keraring for high regular astigmatism
4
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
5





















